Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder Charlotte Marie Pretzsch, Jan Freyberg, Bogdan Voinescu, David Lythgoe, Jamie Horder, Maria Andreina Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Richard A. E. Edden, Steven Williams, Declan G. M. Murphy, Eileen Daly and Gráinne M. McAlonan Neuropsychopharmacology, 2019, 0, 1–8; https://doi.org/10.1038/s41386-019-0333-8 Abstract : There is increasing interest in the use of cannabis and its major non-intoxicating component cannabidiol (CBD) as a treatment for mental health and neurodevelopmental disorders, such as autism spectrum disorder (ASD). However, before [...]
Lire la suiteAn Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine Ivan Urits, Matthew Borchart, Morgan Hasegawa, Justin Kochanski, Vwaire Orhurhu, Omar Viswanath Pain and Therapy, 2019, https://link.springer.com/article/10.1007/s40122-019-0114-4 https://doi.org/10.6084/m9.figshare.7619327 ABSTRACT : Cannabis users have long reported therapeutic properties of the plant for a variety of conditions, some of which include nausea, emesis, seizures, cancer, neurogenic diseases and pain control. Research has elucidated many cannabinoid pharmacodynamic and pharmacokinetic properties, expanding the potential use of cannabinoids as a medical therapy. Due to the inconsistent delivery and control of the active components involved with smoking, pharmaceutical companies are investigating and prioritizing routes other than smoke inhalation for therapeutic use of cannabinoids. In [...]
Lire la suiteTherapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Evan C. Rosenberg, Pabitra H. Patra, and Benjamin J. Whalley Epilepsy & Behavior, 2017 May ; 70(Pt B), 319–327 PMID : 28190698 PMCID : PMC5651410 DOI : 10.1016/j.yebeh.2016.11.006 Abstract : The isolation and identification of the discrete plant cannabinoids in marijuana revived interest in analyzing historical therapeutic claims made for cannabis in clinical case studies and anecdotes. In particular, sources as old as the 11th and 15th centuries claimed efficacy for crude marijuana extracts in the treatment of convulsive disorders, prompting a particularly active area of preclinical research into [...]
Lire la suiteConférence des Cannabinoïdes 2019, International Association for Cannabinoid Medicines Appel aux résumés et inscriptions Le conseil d'administration de l'IACM souhaiterait vous inviter à la Conférence des Cannabinoïdes 2019 et présenter vos recherches. Elle se tiendra du 31 Octobre au 2 Novembre 2019 à Berlin, en Allemagne. Le site Web de la conférence avec le programme préliminaire est en ligne pour la soumission des résumés. L'inscription sera très bientôt possible. Les dates limites pour les résumés oraux sont le 30 Juin 2019 et pour les résumés des posters le 30 Août 2019. Si vous souhaitez parrainer la conférence, veuillez contacter l'IACM en envoyant un [...]
Lire la suiteThe dual neuroprotective– neurotoxic profile of cannabinoid drugs Yosef Sarne, Fadi Asaf, Miriam Fishbein, Mikhal Gafni and Ora Keren British Journal of Pharmacology, 2011, 163, 1391–1401 DOI:10.1111/j.1476-5381.2011.01280.x www.brjpharmacol.org Abstract : Extensive in vitro and in vivo studies have shown that cannabinoid drugs have neuroprotective properties and suggested that the endocannabinoid system may be involved in endogenous neuroprotective mechanisms. On the other hand, neurotoxic effects of cannabinoids in vitro and in vivo were also described. Several possible explanations for these dual, opposite effects of cannabinoids on cellular fate were suggested, and it is conceivable that various factors may determine the final outcome of the cannabinoid effect in vivo. [...]
Lire la suiteTaming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Ethan B Russo British Journal of Pharmacology, 2011, 163, 7, 1344–1364. doi:10.1111/j.1476-5381.2011.01238.x Abstract Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene [...]
Lire la suiteThe pharmacological properties of cannabis Istok Nahtigal, Alexia Blake, Andrew Hand, Angelique Florentinus-Mefailoski, Haleh Hashemi, and Jeremy Friedberg Journal of Pain Management, 2016, 9, 4, 481-491 https://www.researchgate.net/publication/316545895 Abstract : The efforts to understand the nature of how the consumption of cannabis affects the human body are ongoing, complex, and multifaceted. Documentation on the use of cannabis dates back thousands of years; however, it is only now with the recent softening of legal restrictions that modern research approaches have been able to initiate an appropriate level of detailed investigations. For clinicians, researchers and policy makers, this chapter reviews the general structure of cannabinoids, the current understanding [...]
Lire la suiteAnti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia Sepideh Khaksar, Mohammad Reza Bigdeli European Journal of Pharmacology, 2017, 794, 270-279 DOI : 10.1016/j.ejphar.2016.11.011 A B S T R A C T Excitotoxicity and imbalance of sodium and calcium homeostasis trigger pathophysiologic processes in cerebral ischemia which can accelerate neuronal death. Neuroprotective role of cannabidiol (CBD), one of the main nonpsychoactive phytocannabinoids of the cannabis plant, has attracted attention of many researchers in the neurodegenerative diseases studies. The present investigation was designed to determine whether cannabidiol can alleviate the severity of ischemic damages and [...]
Lire la suiteThe pharmacokinetics and the pharmacodynamics of cannabinoids Catherine J. Lucas, Peter Galettis and Jennifer Schneider British Journal of Clinical Pharmacology, 2018, 84, 2477–2482 DOI:10.1111/bcp.13710 Abstract : There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers. Cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta-9-tetrahydrocannabinol (THC), which is psychoactive, and the nonpsychoactive cannabidiol (CBD). Cannabis use is associated with both pathological and behavioural toxicity and, accordingly, is contraindicated in the context of significant psychiatric, cardiovascular, renal or hepatic illness. The pharmacokinetics of cannabinoids and the [...]
Lire la suiteOral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence. Chittaranjan Andrade Journal of Clinical Psychiatry, 2019, 80, 2, 19f12820. https://doi.org/10.4088/JCP.19f12820 Abstract Clinical evidence is accumulating to support the use of ketamine as a powerful, quick-acting intervention for depression. Ketamine has been administered by oral, sublingual, transmucosal, intravenous, intramuscular, subcutaneous, intranasal, and even rectal routes. Whereas intravenous ketamine is the best studied approach, common sense dictates that oral ketamine is the most practical. The bioavailability of oral ketamine and interindividual variations thereof have been poorly studied; possibly only 20%-25% of an oral dose reaches the bloodstream. This is not necessarily a limitation because, as with [...]
Lire la suite